VTRS – Viatris Inc.
Viatris Inc.VTRS
$9.01Name : Viatris Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $10,574,857,216.00
EPSttm : -3.18
Viatris Inc.
$9.01
1.21%$0.11Float Short %
3.75
Margin Of Safety %
-24
Put/Call OI Ratio
0.3
EPS Next Q Diff
0.11
EPS Last/This Y
-0.44
EPS This/Next Y
0.22
Price
9
Target Price
10.83
Analyst Recom
2.7
Performance Q
1.92
Relative Volume
1.22
Beta
0.9
Ticker: VTRS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | VTRS | 8.7 | 0.29 | 0.45 | 151012 |
| 2025-06-03 | VTRS | 8.72 | 0.30 | 0.38 | 151188 |
| 2025-06-04 | VTRS | 8.59 | 0.30 | 2.21 | 151283 |
| 2025-06-05 | VTRS | 8.45 | 0.30 | 0.29 | 152241 |
| 2025-06-06 | VTRS | 8.7 | 0.30 | 0.13 | 152333 |
| 2025-06-09 | VTRS | 8.81 | 0.30 | 0.49 | 157127 |
| 2025-06-10 | VTRS | 9.05 | 0.30 | 0.63 | 158039 |
| 2025-06-11 | VTRS | 8.98 | 0.30 | 0.60 | 158614 |
| 2025-06-12 | VTRS | 9.1 | 0.30 | 0.45 | 159248 |
| 2025-06-13 | VTRS | 8.92 | 0.30 | 0.09 | 159259 |
| 2025-06-16 | VTRS | 8.98 | 0.30 | 1.34 | 159221 |
| 2025-06-17 | VTRS | 8.75 | 0.30 | 0.31 | 159546 |
| 2025-06-18 | VTRS | 8.77 | 0.30 | 0.75 | 159760 |
| 2025-06-20 | VTRS | 8.85 | 0.30 | 0.35 | 159824 |
| 2025-06-23 | VTRS | 8.85 | 0.30 | 0.52 | 150334 |
| 2025-06-24 | VTRS | 8.94 | 0.30 | 0.27 | 151539 |
| 2025-06-25 | VTRS | 8.9 | 0.30 | 1.12 | 152072 |
| 2025-06-26 | VTRS | 9.13 | 0.30 | 0.76 | 152189 |
| 2025-06-27 | VTRS | 9 | 0.30 | 0.14 | 152159 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | VTRS | 8.70 | -20.4 | 3635.8 | 2.22 |
| 2025-06-03 | VTRS | 8.71 | -20.4 | 3637.0 | 2.22 |
| 2025-06-04 | VTRS | 8.59 | -20.4 | 3635.3 | 2.22 |
| 2025-06-05 | VTRS | 8.46 | -20.4 | 3635.2 | 2.22 |
| 2025-06-06 | VTRS | 8.70 | -20.4 | 3639.8 | 2.22 |
| 2025-06-09 | VTRS | 8.81 | -20.4 | 3638.0 | 2.22 |
| 2025-06-10 | VTRS | 9.04 | -20.2 | 3639.5 | 2.21 |
| 2025-06-11 | VTRS | 8.99 | -20.2 | 3636.2 | 2.21 |
| 2025-06-12 | VTRS | 9.09 | -20.2 | 3638.1 | 2.21 |
| 2025-06-13 | VTRS | 8.92 | -20.2 | 3634.8 | 2.21 |
| 2025-06-16 | VTRS | 8.99 | -20.2 | 3637.6 | 2.21 |
| 2025-06-17 | VTRS | 8.76 | -20.2 | 3634.0 | 2.21 |
| 2025-06-18 | VTRS | 8.77 | -20.2 | 3636.9 | 2.21 |
| 2025-06-20 | VTRS | 8.87 | -20.2 | 3638.0 | 2.21 |
| 2025-06-23 | VTRS | 8.85 | -20.2 | 3636.5 | 2.21 |
| 2025-06-24 | VTRS | 8.94 | -20.2 | 3637.8 | 2.21 |
| 2025-06-25 | VTRS | 8.89 | -20.2 | 3636.1 | 2.21 |
| 2025-06-26 | VTRS | 9.13 | -20.2 | 3639.6 | 2.21 |
| 2025-06-27 | VTRS | 9.00 | -20.2 | 3635.4 | 2.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | VTRS | 0.20 | -2.30 | 4.52 |
| 2025-06-03 | VTRS | 0.20 | -2.30 | 4.52 |
| 2025-06-04 | VTRS | 0.20 | -2.30 | 4.52 |
| 2025-06-05 | VTRS | 0.20 | -2.30 | 4.52 |
| 2025-06-06 | VTRS | 0.20 | -2.30 | 4.52 |
| 2025-06-09 | VTRS | 0.20 | -2.31 | 4.52 |
| 2025-06-10 | VTRS | 0.20 | -2.31 | 4.52 |
| 2025-06-11 | VTRS | 0.20 | -2.31 | 4.32 |
| 2025-06-12 | VTRS | 0.20 | -2.31 | 4.32 |
| 2025-06-13 | VTRS | 0.20 | -2.31 | 4.32 |
| 2025-06-16 | VTRS | 0.20 | -1.64 | 4.32 |
| 2025-06-18 | VTRS | 0.20 | -1.64 | 4.32 |
| 2025-06-20 | VTRS | 0.20 | -1.64 | 4.32 |
| 2025-06-23 | VTRS | 0.20 | -2.63 | 4.32 |
| 2025-06-24 | VTRS | 0.20 | -2.63 | 4.32 |
| 2025-06-25 | VTRS | 0.20 | -2.63 | 4.32 |
| 2025-06-26 | VTRS | 0.20 | -2.63 | 3.76 |
| 2025-06-27 | VTRS | 0.22 | -2.63 | 3.75 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.5
Avg. EPS Est. Current Quarter
0.55
Avg. EPS Est. Next Quarter
0.61
Insider Transactions
0.22
Institutional Transactions
-2.63
Beta
0.9
Average Sales Estimate Current Quarter
3455
Average Sales Estimate Next Quarter
3608
Fair Value
6.87
Quality Score
40
Growth Score
35
Sentiment Score
90
Actual DrawDown %
52.3
Max Drawdown 5-Year %
-54.3
Target Price
10.83
P/E
Forward P/E
3.7
PEG
P/S
0.74
P/B
0.68
P/Free Cash Flow
5.55
EPS
-3.18
Average EPS Est. Cur. Y
2.21
EPS Next Y. (Est.)
2.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-26.57
Relative Volume
1.22
Return on Equity vs Sector %
-48.1
Return on Equity vs Industry %
-31.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
3635.4
Viatris Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 32000
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
stock quote shares VTRS – Viatris Inc. Stock Price stock today
news today VTRS – Viatris Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VTRS – Viatris Inc. yahoo finance google finance
stock history VTRS – Viatris Inc. invest stock market
stock prices VTRS premarket after hours
ticker VTRS fair value insiders trading